TRATAMENTO DA DISTIMIA (TRANSTORNO DEPRESSIVO PERSISTENTE): ABORDAGENS SUSTENTADAS PARA CONTROLE A LONGO PRAZO E ALCANCE DA REMISSÃO
DOI:
https://doi.org/10.71248/6v4p3x96Keywords:
Antidepressivos, Psicoterapia, Recidiva, Transtorno DistímicoAbstract
Objetivou-se analisar as evidências científicas sobre as abordagens terapêuticas utilizadas no tratamento da distimia, atualmente denominada transtorno depressivo persistente, com ênfase no controle prolongado dos sintomas e na remissão sustentada. Trata-se de revisão integrativa da literatura, realizada em março de 2026, nas bases Medical Literature Analysis and Retrieval System Online (MEDLINE), Índice Bibliográfico Español en Ciencias de la Salud (IBECS) e Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), incluindo estudos completos em português, inglês e espanhol sobre intervenções farmacológicas, psicoterapêuticas ou combinadas em adultos. Os resultados mostraram que o Cognitive Behavioral Analysis System of Psychotherapy (CBASP), os antidepressivos e as estratégias de continuação e manutenção apresentaram os achados mais consistentes para redução sintomática, prevenção de recaídas e alcance de remissão. Observou-se ainda que fatores como trauma infantil, gravidade clínica e ansiedade comórbida podem influenciar a resposta terapêutica. Conclui-se que o manejo da distimia requer cuidado contínuo, individualizado e orientado ao longo prazo, com seguimento prolongado para melhores desfechos clínicos e funcionais.
References
ACERO‐GONZÁLEZ, Angela et al. Lithium Augmentation in Treatment‐Resistant Depression: A Qualitative Review of the Literature. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, v. 45, n. 10, p. 688–701, 23 out. 2025.
ASSMANN, Nele et al. Moderating effect of comorbid anxiety disorders on treatment outcome in a randomized controlled psychotherapy trial in early-onset persistently depressed outpatients. Depress Anxiety, v. 35, n. 10, p. 1001–1008, 2018.
ATAGÜN, Murat İlhan. Longitudinal trajectories of major depressive disorder provide further clinical perspectives for precision psychiatry. Psychiatry and Clinical Neurosciences Reports, v. 4, n. 4, 12 dez. 2025.
AYAD, Nawfel et al. Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions. BJPsych Open, v. 12, n. 1, p. e48, 23 jan. 2026.
BALLÚS, C. et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol, v. 15, n. 1, p. 43–48, 2000.
BARRETT, J. E. et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract, v. 50, n. 5, p. 405–412, 2001.
BELLAMY, Erin L. A retrospective evaluation of an online group ketogenic metabolic therapy intervention on mental health outcomes. Frontiers in Nutrition, v. 13, 4 mar. 2026.
CIHAROVA, Marketa et al. Modifiers in Effects of Combined Pharmacotherapy and Psychotherapy versus Pharmacotherapy Alone for Adult Depression: An Individual Participant Data Meta-Analysis. Psychotherapy and Psychosomatics, p. 1–18, 21 jan. 2026.
DEL PORTO, José Alberto. Conceito e diagnóstico. Revista Brasileira de Psiquiatria, v. 21, n. suppl 1, p. 06–11, maio 1999.
DEVANAND, D. P. et al. An open treatment trial of venlafaxine for elderly patients with dysthymic disorder. J Geriatr Psychiatry Neurol, v. 17, n. 4, p. 219–224, 2004.
DUNNER, D. L. Acute and maintenance treatment of chronic depression. J Clin Psychiatry, v. 62 Suppl 6, p. 10–16, 2001.
DUNNER, David L. et al. Dysthymic disorder: treatment with citalopram. Depress Anxiety, v. 15, n. 1, p. 18–22, 2002.
GIGUÈRE, Sabrina et al. Effectiveness of Psychological Therapy for Treatment-Resistant Depression in Adults: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, v. 15, n. 8, p. 338, 1 ago. 2025.
GOERIGK, Stephan et al. Childhood Trauma Questionnaire-based child maltreatment profiles to predict efficacy of the Cognitive Behavioral Analysis System of Psychotherapy versus non-specific psychotherapy in adults with early-onset chronic depression: cluster analysis of data from a randomised controlled trial. Lancet Psychiatry, v. 11, n. 9, p. 709–719, 2024.
HELLERSTEIN, D. J. et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality. Am J Psychiatry, v. 157, n. 9, p. 1436–1444, 2000.
HELLERSTEIN, David J. et al. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. J Clin Psychiatry, v. 73, n. 7, p. 984–991, 2012.
HELLERSTEIN, David J. et al. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study. J Affect Disord, v. 210, p. 258–264, 2017.
KHAN, Aqsa Zarin et al. A holistic Ayurvedic approach to manage persistent depressive disorder, Vishada—A case report. Journal of Ayurveda and Integrative Medicine, v. 16, n. 6, p. 101243, nov. 2025.
KOCSIS, J. H. et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry, v. 45, n. 3, p. 253–257, 1988.
KORAN, L. M. et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord, v. 65, n. 1, p. 27–36, 2001.
KORAN, Lorrin M.; ABOUJAOUDE, Elias N.; GAMEL, Nona N. Duloxetine treatment of dysthymia and double depression: an open-label trial. J Clin Psychiatry, v. 68, n. 5, p. 761–765, 2007.
KOWALCZYK, Mateusz et al. Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation. International Journal of Molecular Sciences, v. 27, n. 1, p. 344, 28 dez. 2025.
LAM, Raymond W. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l’humeur et de l’anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. The Canadian Journal of Psychiatry, v. 69, n. 9, p. 641–687, 6 set. 2024.
LIMA, Maurício Silva de. Tratamento farmacológico da distimia: avaliação crítica da evidência científica. Revista Brasileira de Psiquiatria, v. 21, n. 2, p. 128–130, jun. 1999.
LIMA, M. S.; MONCRIEFF, J. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev, n. 4, p. CD001130–CD001130, 2000.
MACHMUTOW, Katja et al. Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. Cochrane Database Syst Rev, v. 5, p. CD012855–CD012855, 2019.
MAJKIC, Ninoslav; TAYLOR, David. Loss of responsiveness on reinstatement of antidepressants after treatment interruption – A systematic review. Journal of Psychopharmacology, v. 39, n. 10, p. 1114–1119, 13 out. 2025.
MALKOMSEN, Anders et al. Comparative effectiveness of short-term psychodynamic psychotherapy and cognitive behavioral therapy for major depression in psychiatric outpatient clinics: a randomized controlled trial. BMC Psychiatry, v. 25, n. 1, p. 113, 11 fev. 2025.
MARKOWITZ, John C. et al. A comparative trial of psychotherapy and pharmacotherapy for “pure” dysthymic patients. J Affect Disord, v. 89, n. 1–3, p. 167–175, 2005.
MILLER, I. W. et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry, v. 59, n. 11, p. 608–619, 1998.
MILLER, N. L. et al. Maintenance desipramine for dysthymia: a placebo-controlled study. J Affect Disord, v. 64, n. 2–3, p. 231–237, 2001.
MOLERO, Patricio et al. The PREDEP-SERT study protocol: A 6-month follow-up cohort study of predictors of effectiveness, tolerability and safety of sertraline for depression using Therapeutic Drug Monitoring. PLOS One, v. 20, n. 8, p. e0325335, 8 ago. 2025.
MURRAY, Greg et al. Relief of chronic or resistant depression (Re-ChORD): a pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression. J Affect Disord, v. 123, n. 1–3, p. 243–248, 2010.
NODA, Yoshihiro et al. Repetitive Transcranial Magnetic Stimulation as Maintenance Treatment of Depression. JAMA Network Open, v. 8, n. 6, p. e2515881, 16 jun. 2025.
OLIVOLA, Miriam et al. Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality. Frontiers in Psychiatry, v. 16, 22 jan. 2026.
OXMAN, T. E. et al. Status of minor depression or dysthymia in primary care following a randomized controlled treatment. Gen Hosp Psychiatry, v. 23, n. 6, p. 301–310, 2001.
Preventing recurrent depression: long-term treatment for major depressive disorder. Primary care companion to the Journal of clinical psychiatry, v. 9, n. 3, p. 214–23, 2007.
RAVINDRAN, Arun V et al. Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. Asian J Psychiatr, v. 6, n. 2, p. 157–161, 2013.
ROCCA, Paola et al. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res, v. 112, n. 2, p. 145–152, 2002.
ROVERS, Jordy J. E. et al. Systematic review on relapse-prevention strategies following successful electroconvulsive therapy for major depressive disorder. BJPsych Open, v. 12, n. 1, p. e37, 14 jan. 2026.
SCHRAMM, Elisabeth et al. Efficacy of psychotherapy versus pharmacotherapy, or their combination, in chronic depression: study protocol for a systematic review and network meta-analysis using aggregated and individual patient data. BMJ Open, v. 15, n. 2, p. e089356, fev. 2025.
SEIDMAN, Stuart N. et al. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. J Clin Psychopharmacol, v. 29, n. 3, p. 216–221, 2009.
SERBANESCU, Ilinca et al. Combining baseline characteristics to disentangle response differences to disorder-specific versus supportive psychotherapy in patients with persistent depressive disorder. Behav Res Ther, v. 124, p. 103512, 2020.
SERBANESCU, Ilinca et al. Identifying subgroups with differential response to CBASP versus Escitalopram during the first eight weeks of treatment in outpatients with persistent depressive disorder. Eur Arch Psychiatry Clin Neurosci, v. 274, n. 3, p. 723–737, 2024.
SMERALDI, E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord, v. 48, n. 1, p. 47–56, 1998.
SPANEMBERG, Lucas; JURUENA, Mario Francisco. Distimia: características históricas e nosológicas e sua relação com transtorno depressivo maior. Revista de Psiquiatria do Rio Grande do Sul, v. 26, n. 3, p. 300–311, dez. 2004.
TALMO, Maren Sophie Aaserud et al. Growth Restriction in the Offspring of Mothers With Polycystic Ovary Syndrome. JAMA Network Open, v. 7, n. 8, p. e2430543, 27 ago. 2024.
THASE, Michael E. et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry, v. 59, n. 3, p. 233–239, 2002.
VODERHOLZER, Ulrich et al. Enduring effects of psychotherapy, antidepressants and their combination for depression: a systematic review and meta-analysis. Frontiers in Psychiatry, v. 15, 27 nov. 2024.
YANG, Jingming et al. Efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in depression with ineffective or partially effective initial antidepressant treatment: a single-arm, multicenter clinical study. Frontiers in Psychiatry, v. 16, 5 fev. 2026.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Cognitus Interdisciplinary Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
